Back to Browse Journals » Vascular Health and Risk Management » Volume 4 » Issue 4

Tobacco smoking cessation management: integrating varenicline in current practice

Authors Laurence M Galanti

Published 8 August 2008 Volume 2008:4(4) Pages 837—845


Review by Single-blind

Peer reviewer comments 3

Laurence M Galanti

Clinique Universitaire UCL, Mont-Godinne, Yvoir, Belgium

Abstract: Tobacco smoking is widespread and is one of the world’s most prevalent modifiable risk factors for morbidity and mortality. It is important to facilitate smoking cessation better in order to reduce the health consequences of tobacco use. The most effective approach assisting smokers in their quit attempts combines both pharmacotherapy and nonpharmacological interventions. This review summarizes the latest international epidemiological data available on tobacco use, considers the associated effects on health, and reviews existing policies against tobacco use. Among the interventions for smoking cessation, the three major pharmacotherapies (which have demonstrated efficacy when combined with behavioral support) are discussed: nicotine replacement therapy (NRT), bupropion, and varenicline. As the newest pharmacotherapy made available in this area, particular consideration is given to varenicline, and a review of our clinical experience is offered.

Keywords: tobacco smoking cessation, nicotinic substitution, nicotine replacement therapy (NRT), bupropion, varenicline

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Readers of this article also read:

Effects of pitavastatin on plasminogen activator inhibitor-1 in hyperlipidemic patients

Nomura S, Taniura T, Shouzu A, Omoto S, Inami N, Fujita S, Tamaki T, Yokoi T, Shimizu T, Ito T

International Journal of General Medicine 2012, 5:535-540

Published Date: 18 June 2012

The interaction between clopidogrel and proton pump inhibitors (PPI): is there any clinical relevance?

Rakesh K Sharma, Hanumanth K Reddy, Rohit K Sharma, et al

Clinical Pharmacology: Advances and Applications 2010, 2:155-162

Published Date: 6 September 2010

Effectiveness of percutaneous laser revascularization therapy for refractory angina

Michael McGillion, Allison Cook, J Charles Victor, et al

Vascular Health and Risk Management 2010, 6:735-747

Published Date: 26 August 2010

Pyocele of the lachrymal sac: A late and unusual complication after surgery for a juvenile nasopharyngeal angiofibroma

Philippe Eloy, Vincent Bachy, Véronique Grulois, Bernard Bertrand

Clinical Ophthalmology 2008, 2:211-215

Published Date: 7 March 2008

Severe supraaortal atherosclerotic disease resembling Takayasu’s Arteritis

Bernhard Kis, Thomas Liebig, Peter Berlit

Vascular Health and Risk Management 2007, 3:351-354

Published Date: 15 July 2007

Effect of alcohol on risk of coronary heart disease and stroke: causality, bias, or a bit of both?

Jonathan R Emberson, Derrick A Bennett

Vascular Health and Risk Management 2006, 2:239-249

Published Date: 15 September 2006

The use of metoprolol CR/XL in the treatment of patients with diabetes and chronic heart failure

Ovidio De Freitas, Oliver Lenz, Alessia Fornoni, Barry J Materson

Vascular Health and Risk Management 2006, 2:139-144

Published Date: 15 June 2006

Plant sterols as dietary adjuvants in the reduction of cardiovascular risk: theory and evidence

Craig S Patch, Linda C Tapsell, Peter G Williams, Michelle Gordon

Vascular Health and Risk Management 2006, 2:157-162

Published Date: 15 June 2006